AJBS Asian Journal of Biological Sciences

OPEN ACCESS

Pushing the Frontiers in Immuno-Oncology

Kaiser Jamil

Department of Emeritus Scientist and Head of Genetics, Bhagwan Mahavir Medical Research Centre, 10-1-1, Mahavir Marg, A.C. Guards, Hyderabad-500004, Telangana, India

In recent years, immuno-oncology (I-O) has sparked a paradigm shift in cancer therapy, leveraging the body's immune system to recognize and destroy cancer cells. As research continues to unravel the complexities of tumor immunity, several groundbreaking advances are redefining patient care. Immuno-oncology (I-O) has transformed the cancer treatment landscape, with recent advancements providing renewed hope for patients with challenging cancers, the latest developments in this ever-evolving field are:

- **Novel checkpoint inhibitors:** The PD-1 and CTLA-4 inhibitors have set the foundation for I-O, but novel immune checkpoint targets are emerging. Recently, the LAG-3 (Lymphocyte-activation Gene 3) inhibitor received regulatory approval, signaling a new era of immune modulation. The LAG-3, which inhibits T-cell activity, complements the action of PD-1/PD-L1 inhibitors, potentially enhancing anti-tumor immunity. Trials combining LAG-3 inhibitors with traditional checkpoint inhibitors are already showing promise for patients with advanced melanoma, a condition previously resistant to standard therapies
- **Personalized cancer vaccines:** Cancer vaccines are witnessing a renaissance, shifting focus from a broad approach to a highly personalized one. These vaccines are designed to present tumor-specific antigens, stimulating an immune response tailored to the patient's tumor profile. Recent clinical trials, particularly for melanoma and pancreatic cancer, demonstrate that personalized neoantigen vaccines can achieve significant clinical responses, especially when combined with checkpoint inhibitors. Advances in sequencing technologies and bioinformatics allow for rapid and cost-effective identification of unique tumor mutations, making personalized vaccines increasingly feasible
- **Oncolytic viruses:** Oncolytic virotherapy is an innovative approach where genetically modified viruses selectively infect and kill tumor cells while sparing normal tissues. The FDA has approved oncolytic viruses for melanoma and several new candidates are in clinical trials. One promising candidate involves the herpes simplex virus, engineered to express GM-CSF, which promotes a robust anti-tumor immune response. These viruses not only destroy tumor cells but also serve as immunogenic adjuvants, stimulating systemic immunity against the cancer
- **Adoptive cell therapy:** Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in hematologic malignancies but faces challenges in solid tumors. Recently, dual-target CAR-T cells, which recognize two tumor antigens, have shown promise in overcoming solid tumor resistance by reducing antigen escape. Further, TIL (tumor-infiltrating lymphocyte) therapy, where T-cells extracted from a patient's tumor are expanded and reinfused, is gaining traction, particularly in metastatic melanoma and certain ovarian cancers. These strategies hold great promise for expanding the reach of adoptive cell therapies beyond blood cancers

ISSN: 1996-3351 (Print)
https://doi.org/10.3923/ajbs.2025.223.224

Received: 26 Oct. 2024
Accepted: 14 Dec. 2024
Published: 31 Mar. 2025

- **Tumor microenvironment modulation:** The tumor microenvironment (TME) has a profound impact on the immune system's ability to eradicate tumors. Recent research focuses on altering the TME to promote a pro-immunogenic state. For instance, therapies targeting Myeloid-Derived Suppressor Cells (MDSCs) and regulatory T-cells (Tregs) are being developed to diminish immune suppression within tumors. Additionally, anti-fibrotic agents are being tested to modify the TME in pancreatic cancer, enhancing immune cell infiltration and responsiveness to I-O therapies
- **Microbiome and immune response:** Emerging evidence links gut microbiota composition to I-O efficacy, suggesting that a patient's microbiome may influence response to checkpoint inhibitors. Clinical trials are investigating whether microbiome modulation, through probiotics or fecal microbiota transplants, can improve treatment outcomes. Preliminary results suggest that patients with specific microbiota profiles exhibit better responses, opening doors to microbiome-based therapies that may optimize the efficacy of immune-based treatments
- **Biomarkers for response prediction:** Predicting patient response to I-O therapy remains a critical challenge. New biomarkers, such as TMB (tumor mutational burden) and IFN-γ gene signatures, provide insights into the likelihood of response, enabling personalized treatment planning. Circulating Tumor DNA (ctDNA) and immune-related gene expression profiles are also under investigation as non-invasive biomarkers to monitor treatment response in real-time. By incorporating these predictive markers, clinicians can better tailor I-O therapies, potentially sparing non-responders from unnecessary side effects
- **AI in immuno-oncology:** Artificial Intelligence (AI) is transforming I-O research, aiding in biomarker discovery, patient stratification and drug development. Machine learning models analyze vast datasets, identifying patterns that can predict treatment outcomes. AI-driven analysis of histopathology images, for example, is helping to identify microenvironmental features linked to immune response. These insights may streamline the development of new therapies and guide clinical decision-making in ways previously unimaginable

The future of I-O appears brighter than ever, with a strong pipeline of innovative therapies poised to overcome existing limitations. As we harness these new advances, the hope is to transition from a one-size-fits-all approach to a personalized cancer immunotherapy model, ensuring patients receive the most effective and tailored treatments. The promise of I-O lies not only in extending life but in offering cancer patients a significantly improved quality of life, with durable responses and potentially long-term remissions. For oncologists and patients alike, the excitement is palpable as we stand on the cusp of a new era in cancer care.

KEYWORDS
Cancer, immuno-oncology (OI), checkpoint inhibitors, tumour microenvironment, biomarkers, microbiome